Overview

Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods

Status:
Completed
Trial end date:
2001-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the pharmacokinetics of BTDS following same-site patch reapplication after rest intervals.
Phase:
Phase 1
Details
Lead Sponsor:
Purdue Pharma LP
Treatments:
Buprenorphine